Cargando…

MBRS-67. ROLE OF CYCLIN DEPENDENT KINASE-9 IN Myc-ENHANCED MEDULLOBLASTOMA

Myc is highly expressed in group 3 medulloblastoma (Myc-MB) and influences cell growth, proliferation and oncogenesis by directly promoting the activity of RNA polymerases (RNA Pol). Myc driven RNA Pol II activity is mediated by Positive Transcription Elongation Factor b (pTEFb). pTEFb’s catalytic c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madhavan, Krishna, Veo, Bethany, Danis, Etienne, Balakrishnan, Ilango, Pierce, Angela, Wang, Dong, Abdel-Hafiz, Ahmed, Serkova, Natalie, Dahl, Nathan, Venkataraman, Sujatha, Vibhakar, Rajeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Medulloblastoma (Research)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715077/ http://dx.doi.org/10.1093/neuonc/noaa222.571

Ejemplares similares

MBRS-71. ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN ATTENUATES DNA DAMAGE AND IS A THERAPEUTIC TARGET IN Myc-DRIVEN MEDULLOBLASTOMA
por: Abdel-Hafiz, Ahmed, et al.
Publicado: (2020)

MBRS-65. FBXW7 ACTS A TUMOR SUPPRESSOR IN MYC-DRIVEN MEDULLOBLASTOMA BY CONTROLLING A FEED-FORWARD REGULATORY LOOP OF PLK1 AND MYC
por: Wang, Dong, et al.
Publicado: (2020)

MBRS-26. CDK7 MEDIATED TRANSCRIPTIONAL PROCESSIVITY OF DNA REPAIR NETWORKS REGULATES SENSITIVITY TO RADIATION IN MYC DRIVEN MEDULLOBLASTOMA
por: Veo, Bethany, et al.
Publicado: (2020)

MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

MEDB-28. CDK9 is a druggable mediator sustaining Myc-driven circuitry in medulloblastoma
por: Madhavan, Krishna, et al.
Publicado: (2022)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

MEDB-70. Metabolism mediated radiation resistance in MYC-driven Medulloblastoma
por: Veo, Bethany, et al.
Publicado: (2022)

MDB-37. CDK9 IS A DRUGGABLE MEDIATOR SUSTAINING MYC-DRIVEN TRANSCRIPTIONAL CIRCUITRY IN MEDULLOBLASTOMA
por: Krishna, Madhavan, et al.
Publicado: (2023)

MBRS-46. CHARTING NEOPLASTIC AND IMMUNE CELL HETEROGENEITY IN HUMAN AND GEM MODELS OF MEDULLOBLASTOMA USING scRNAseq
por: Donson, Andrew, et al.
Publicado: (2020)

A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma
por: Wang, Dong, et al.
Publicado: (2021)

MBRS-48. IDENTIFICATION OF NOVEL THERAPEUTIC APPROACHES FOR MYC-DRIVEN MEDULLOBLASTOMA
por: Taban, Kübra, et al.
Publicado: (2020)

MEDB-44. Transcriptomic resolution of subgroup-specific medulloblastoma architecture
por: Willard, Nicholas, et al.
Publicado: (2022)

MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA
por: Llargués-Sistac, Gemma, et al.
Publicado: (2020)

MBRS-16. MYC REGULATED LONG NONCODING RNA LNC-HLX-2–7 IS A PUTATIVE MOLECULAR MARKER AND A THERAPEUTIC TARGET FOR GROUP 3 MEDULLOBLASTOMAS IN CHILDREN
por: Katsushima, Keisuke, et al.
Publicado: (2020)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE
por: Bolin, Sara, et al.
Publicado: (2020)

MBRS-04. MEDULLOBLASTOMA DETECTION BY BLOOD TEST
por: Yalon, Michal, et al.
Publicado: (2020)

MBRS-01. DISSECTING REGULATORS OF THE ABERRANT POST-TRANSCRIPTIONAL LANDSCAPE IN MYC-AMPLIFIED GROUP 3 MEDULLOBLASTOMA
por: Kameda-Smith, Michelle, et al.
Publicado: (2020)

MDB-26. CDK8 IS AN ONCOGENE IN GROUP 3 MEDULLOBLASTOMA THAT IMPACTS PROTEIN TRANSLATION BY REGULATING THE TRANSCRIPTIONAL ACTIVITY OF RIBOSOMAL GENES
por: Wang, Dong, et al.
Publicado: (2023)

MBRS-64. STUDY OF ARGININE METHYL TRANSFERASES IN MEDULLOBLASTOMA
por: Cheng, Donghang, et al.
Publicado: (2020)

MBRS-22. SIGNIFICANCE OF RNF213 IN TUMORGENICITY OF MEDULLOBLASTOMA
por: Mineharu, Yohei, et al.
Publicado: (2020)

MBRS-62. CURAXIN CBL0137 INHIBITS THE VIABILITY OF CANCEROUS CELLS IN PRE-CLINIC MODELS OF MYC-AMPLIFIED MEDULLOBLASTOMA
por: Wang, Jiajia, et al.
Publicado: (2020)

MBRS-53. CONTROL OF MEDULLOBLASTOMA VASCULATURE BY A REGULATOR OF NEUROGENESIS
por: Shaik, Shavali, et al.
Publicado: (2020)

MBRS-70. FUNCTIONAL DEPENDENCY BETWEEN REST AND DNMT1 IN MEDULLOBLASTOMA
por: Maegawa, Shinji, et al.
Publicado: (2020)

MBRS-23. SIGNIFICANCE OF mi-R33 IN GENERATION AND PROGRESSION OF MEDULLOBLASTOMA
por: Matsui, Yasuzumi
Publicado: (2020)

MBRS-38. MOLECULAR CLASSIFICATION AND CLINICAL CHARACTERISTICS OF 236 MEDULLOBLASTOMAS IN JAPAN
por: Kanemura, Yonehiro, et al.
Publicado: (2020)

MBRS-17. EXAMINING THE ROLE OF LHX9 IN GROUP 3 MEDULLOBLASTOMA
por: Injac, Sarah, et al.
Publicado: (2020)

MBRS-37. RECURRENT ACTIVATING MUTATIONS OF AKT GENES IN WNT-ACTIVATED MEDULLOBLASTOMAS
por: Masliah-Planchon, Julien, et al.
Publicado: (2020)

MBRS-63. THE ROLE OF THE SWI/SNF COMPLEX SUBUNIT SMARCD3 IN MEDULLOBLASTOMA
por: Poore, Brad, et al.
Publicado: (2020)

MBRS-45. TWIST1 AND ABCB1 ARE FUNCTIONAL DETERMINANTS OF METASTASIS IN MEDULLOBLASTOMA
por: Cardall, Alice, et al.
Publicado: (2020)

MBRS-32. TOPOISOMERASE II β INDUCES NEURONAL, BUT NOT GLIAL, DIFFERENTIATION IN MEDULLOBLASTOMA
por: Miyahara, Hiroaki, et al.
Publicado: (2020)

MBRS-02. BET BROMODOMAIN PROTEIN-KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF MEDULLOBLASTOMA
por: Ayad, Nagi, et al.
Publicado: (2020)

MBRS-27. EXOSOMES CARRY DISTINCT miRNAs THAT DRIVE MEDULLOBLASTOMA PROGRESSION
por: Jackson, Hannah K, et al.
Publicado: (2020)

MBRS-42. YB-1 - A NOVEL THERAPEUTIC TARGET IN HIGH-RISK MEDULLOBLASTOMA?
por: Taylor, Louisa, et al.
Publicado: (2020)

MBRS-18. TUMOR SUPPRESSOR p53 DEFINES THE THERAPEUTIC RESPONSES IN TREATMENT OF MEDULLOBLASTOMA
por: Mohan, Avinash L, et al.
Publicado: (2020)

MBRS-47. RAPID MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA BASED ON DNA METHYLATION BY NANOPORE SEQUENCING
por: Masliah-Planchon, Julien, et al.
Publicado: (2020)

MBRS-06. Gli3 INDUCES NEURONAL DIFFERENTIATION IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA
por: Natsumeda, Manabu, et al.
Publicado: (2020)

MEDB-67. Subgroup specific analysis of cellular metabolism in medulloblastoma
por: Funke, Viktoria, et al.
Publicado: (2022)

MBRS-31. COMBINING IRRADIATION AND ANTI-CD47 TO ENHANCE THE TREATMENT OF GROUP 3 MEDULLOBLASTOMA
por: Youssef, Osama, et al.
Publicado: (2020)

MBRS-28. EXOSOMES DRIVE MEDULLOBLASTOMA METASTASIS IN A MMP2 AND EMMPRIN DEPENDENT MANNER
por: Jackson, Hannah K, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qfblif472uqcd80rqm685ivlrg